bims-kimdis Biomed News
on Ketones, inflammation and mitochondria in disease
Issue of 2025–03–16
twenty-six papers selected by
Matías Javier Monsalves Álvarez, Universidad Andrés Bello



  1. Curr Nutr Rep. 2025 Mar 08. 14(1): 43
       PURPOSE OF REVIEW: The ketogenic diet (KD) has gained clinical attention for its potential benefits in weight loss and metabolic syndrome. By mimicking fasting through carbohydrate (CHO) restriction, KD shifts energy utilization to ketone bodies (KB) instead of glucose. Despite promising results, the effects on different weight loss indicators remain controversial, with challenges in monitoring adherence standards, optimal macronutrient composition, potential risks, and long-term sustainability. This article aims to review the different weight-loss outcomes of KD interventions for obesity, monitored by KB (adherence indication).
    RECENT FINDINGS: Current literature on KD interventions for obesity weight loss monitored by KB show reduction in different outcomes, including body weight, body mass index, waist circumference, visceral adipose tissue, fat mass, and body fat percentage. Minor decreases in lean body mass and skeletal muscle mass were noted without resistance training. Variability existed in adherence (KB markers), CHO intake (7-27% of daily energy), diet duration (28 days to 12 months), and follow-up frequency (weekly to biannual). KD, particularly accompanied by exercise, positively influenced appetite regulation. KD interventions improves weight-related outcomes in participants with obesity but presents challenges in lean body mass reduction without resistance training and adherence variability. Standardizing methodologies, refining interventions and suitability to sub-populations, setting KB markers, and defining clinical relevance are essential for optimizing KD effectiveness.
    Keywords:  Adherence; Ketogenic diet; Ketone bodies; Lean body mass; Obesity; Weight reduction
    DOI:  https://doi.org/10.1007/s13668-025-00634-3
  2. BMC Nephrol. 2025 Mar 07. 26(1): 127
      Diabetic kidney disease (DKD) is the main cause of end-stage renal disease. Ketogenic diets (KD) is a high-fat, low-carbohydrate diet. KD produces ketone bodies to supplement energy in the case of insufficient glucose in the body. β-Hydroxybutyrate (BHB) is the main component of ketone bodies. BHB serves as "ancillary fuel" substituting (but also inducing) anti-oxidative, anti-inflammatory, and cardio-protective features by binding to several target proteins, including histone acylation modification, or G protein-coupled receptors (GPCRs). KD have been used to treat epilepsy, obesity, type-2 diabetes mellitus, polycystic ovary syndrome, cancers, and other diseases. According to recent research, KD and the induced BHB delay DKD progression by improving the metabolism of glucose and lipids, regulating autophagy, as well as alleviating inflammation, oxidative stress and fibrosis. However, due to some side-effects, the role and mechanism of action of KD and BHB in the prevention and treatment of DKD are controversial. This review focuses on recent progress in the research of KD and BHB in clinical and preclinical studies of DKD, and provides new perspectives for DKD treatment.
    Keywords:  Diabetic kidney disease (DKD); Ketogenic diets (KD); β-hydroxybutyrate (BHB)
    DOI:  https://doi.org/10.1186/s12882-025-04019-0
  3. bioRxiv. 2025 Feb 26. pii: 2025.02.24.639075. [Epub ahead of print]
      Asthma is a chronic respiratory condition characterized by airway inflammation, remodeling, and hyperresponsiveness to triggers causing airway constriction. Bronchial smooth muscle plays a critical role by narrowing airways, leading to obstruction and breathing difficulties, often exacerbated by mast cell infiltration and histamine release. Whereas current treatments, including bronchodilators, corticosteroids, and biologics provide effective management for most patients, alternative therapies are needed for difficult-to-treat asthma. Recent research highlights the potential of therapeutic ketosis, achieved through dietary interventions or supplementation with exogenous ketones, to reduce airway hyperresponsiveness and inflammation. Ketone bodies, known for providing energy during carbohydrate scarcity, also influence asthma by activating cell-surface receptors and transporters. In vivo , interventions like weight loss and caloric restriction increase ketone body levels, correlating with improved asthma symptoms, reduced oxidative stress, and inflammation. These effects suggest ketone bodies, particularly β-hydroxybutyrate, may play a therapeutic role in mitigating bronchoconstriction and smooth muscle contraction in asthma. We utilize human bronchial smooth muscle cells ( in vitro ) and mouse precision-cut lung slices (PCLS) ( ex vivo ) to assess the effects of BHB on histamine-induced bronchoconstriction. Brightfield microscopy showed that BHB reduces contraction in human bronchial smooth muscle cells, an effect involving free fatty acid receptor 3 (FFAR3) activation. Light microscopy of PCLS revealed that BHB inhibits airway narrowing and cellular extrusion, demonstrating its ability to mitigate bronchoconstriction by suppressing smooth muscle contraction. These results implicate bronchial smooth muscle as a cellular target of therapeutic ketosis, an important contributor to the beneficial effects of BHB in preclinical models of asthma.
    DOI:  https://doi.org/10.1101/2025.02.24.639075
  4. Eur J Heart Fail. 2025 Mar 11.
       AIMS: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiac performance and clinical outcomes in patients with heart failure, yet mechanisms underlying these beneficial effects remain incompletely understood. We sought to determine whether SGLT2i-induced improvements in cardiac function are dependent on increased cardiac oxidation of ketone bodies.
    METHODS AND RESULTS: We employed a mouse model with a cardiac-specific knock-out of the enzyme D-β-hydroxybutyrate dehydrogenase-1 (BDH1cko), rendering mice incapable of oxidizing the principal ketone body β-hydroxybutyrate in cardiomyocytes. Male BDH1cko and littermate controls underwent either permanent coronary artery ligation of the left anterior descending coronary artery to induce myocardial infarction (MI) or sham surgery. Two weeks after surgery, mice were randomized to 6 weeks of empagliflozin or vehicle treatment. Cardiac function was assessed using transthoracic echocardiography before and after treatment, and histological and molecular analyses were performed after sacrifice. Empagliflozin treatment resulted in a twofold increase in circulating ketone bodies. Mean infarct size (36 ± 4% of the left ventricle) was comparable among MI groups. In control mice, empagliflozin treatment resulted in a significant increase in left ventricular ejection fraction (LVEF) whereas LVEF remained stable in the vehicle treated group (ΔLVEF -1.1 ± 2.2% vs. 5.2 ± 1.5%, p < 0.05). Empagliflozin did not influence cardiac contractility in BDH1cko mice (ΔLVEF -5.9 ± 2.1% vs. -1.5 ± 2.8%, p = 0.213). Other echocardiographic, histological and molecular signatures of adverse myocardial remodelling were not affected by empagliflozin treatment.
    CONCLUSION: The beneficial effects of empagliflozin on cardiac contractility in post-MI heart failure are attenuated in mice which are incapable of oxidizing the ketone body β-hydroxybutyrate in their hearts. These findings suggest that enhanced cardiac ketone body oxidation contributes to the cardioprotective effects of SGLT2i.
    Keywords:  BDH1; Empagliflozin; Heart failure; Ketone bodies; Sodium–glucose cotransporter 2 inhibitors
    DOI:  https://doi.org/10.1002/ejhf.3633
  5. Trends Endocrinol Metab. 2025 Mar 07. pii: S1043-2760(25)00025-6. [Epub ahead of print]
      Fasting is a recurrent daily energy stress that benefits healthspan and lifespan. While ketones fuel fasting in vertebrates, the underlying transcriptional mechanism remains incompletely understood. Recently, Korenfeld et al. revealed peroxisome proliferator-activated receptor alpha (PPARα)-dependent enhancer priming as a keystone for ketone production, increasing our understanding of mechanisms underlying metabolic benefits of alternate-day fasting (ADF).
    Keywords:  PPARα transcription factor; alternate-day fasting; enhancers; ketogenesis; transcriptional remodeling
    DOI:  https://doi.org/10.1016/j.tem.2025.02.002
  6. Korean J Fam Med. 2025 Mar 07.
      Ketone bodies produced by sodium-glucose cotransporter 2 (SGLT2) inhibitors can be advantageous, providing an efficient and stable energy source for the brain and muscles. However, in patients with diabetes, ketogenesis induced by SGLT2 inhibitors may be harmful, potentially resulting in severe diabetic ketoacidosis (DKA). During fasting, ketone body production serves as an alternative and efficient energy source for the brain by utilizing stored fat, promoting mental clarity, and reducing dependence on glucose. The concurrent use of SGLT2 inhibitors during perioperative fasting may further elevate the risk of euglycemic DKA. We describe a case of DKA that occurred during perioperative fasting in a patient receiving empagliflozin, an SGLT2 inhibitor. This case underscores the importance of recognizing the potential risk of DKA in patients with diabetes using SGLT2 inhibitors during perioperative fasting.
    Keywords:  Case Reports; Diabetic Ketoacidosis; Fasting; Preoperative Care; Sodium-Glucose Transporter 2 Inhibitors
    DOI:  https://doi.org/10.4082/kjfm.24.0210
  7. bioRxiv. 2025 Feb 24. pii: 2025.02.19.639087. [Epub ahead of print]
      Hyperglycemia in poorly controlled diabetes is widely recognized as detrimental to organ dysfunction. However, the acute effects of hyperglycemia on brain metabolism and function are not fully understood. The potential protective benefit of ketone bodies on mitochondrial function in the brain has also not been well characterized. Here, we evaluated the acute effects of hyperglycemia and β-hydroxybutyrate (BHB) on brain metabolism by employing a novel approach leveraging adenosine triphosphate (ATP)-dependence of bioluminescence originating from luciferin-luciferase activity. Oxygen consumption rate was measured in ex vivo live brain punches to further evaluate mitochondrial function. Additionally, we investigated the functional relevance of BHB using an in vivo photothrombotic stroke model to assess its cerebroprotective effects. Our data demonstrate that brain metabolism in mice is affected by acute exposure to high glucose, at a level similar to consuming food or a beverage with high sucrose. This short-term effect of glucose exposure was reduced by co-administration with the ketone body BHB. Moreover, BHB significantly reduced infarct size in the brain stroke model, providing evidence for its functional protective role in the brain. These findings suggest that BHB may effectively mitigate the adverse effects of metabolic stress and ischemic events on brain metabolism and function.
    DOI:  https://doi.org/10.1101/2025.02.19.639087
  8. Neurochem Res. 2025 Mar 14. 50(2): 118
      Due to the pleiotropic effects of ketogenic diet (KD) on pathophysiology, including inflammation and oxidative stress, medical personnels have been intensively exploring the application of it in the management of epilepsy. Meanwhile, the voltage-dependent anion channel 1 (VDAC1) is believed to be involved in regulating inflammatory and oxidative stress processes. However, the correlation between KD and VDAC1 in epilepsy has not been elucidated. Pilocarpine-induced chronic epilepsy model was utilized to examine the effects of VDAC1 antagonist VBIT-4 treatment on seizure activity, behavioral changes, inflammation, and oxidative stress under control diet (CD) and KD conditions, respectively. Chronic VBIT-4 administration mitigates seizure activity and behavioral abnormalities of epileptic mice under KD rather than CD conditions. Our further findings demonstrated that VBIT-4 treatment attenuates inflammatory response and oxidative stress in the hippocampi and serum samples of epileptic mice under KD rather than CD. Taken together, our data suggest a critical role of VDAC1 in mediating the anti-seizure efficacy of the KD, shedding light on developing novel therapeutic interventions to seizure control.
    Keywords:  Inflammation; Ketogenic diet; Oxidative stress; Seizure activity; Voltage-dependent anion channel 1
    DOI:  https://doi.org/10.1007/s11064-025-04366-2
  9. Forensic Sci Int. 2025 Feb;pii: S0379-0738(24)00440-7. [Epub ahead of print]367 112358
       OBJECTIVES: Ketone bodies, like β-hydroxybutyrate (BHB), derived from fatty acid breakdown, can cause fatal ketoacidosis if levels are excessively high. Postmortem diagnosis of ketoacidosis is challenging due to non-specificity of rapid chromogenic tests and the time required for LC-MS/MS analysis. This study investigates the feasibility of using point-of-care (POC) BHB and glucose testing to diagnose ketoacidosis-related deaths and distinguish between diabetic and other types of ketoacidosis, post-mortem.
    DESIGN AND METHODS: This study evaluated the Nova StatStrip meter's analytical and post-mortem performance for measuring BHB and glucose in decedent whole blood and vitreous humor. Precision, linearity, and recovery were assessed. BHB and glucose were measured in whole blood and vitreous humor from 100 autopsy cases (both ketoacidosis and non-ketoacidosis deaths). Results were compared quantitatively and qualitatively with standard laboratory methods to determine the meter's accuracy and reliability in predicting ketoacidosis-related deaths. Receiver operating characteristic (ROC) curves were constructed for each matrix/analyte combination to evaluate screening capabilities for ketoacidosis- and diabetic ketoacidosis-related deaths.
    RESULTS: Imprecision was highest in decedent vitreous humor samples for both BHB and glucose and both assays exhibited acceptable linearity. ROC curve analysis indicated comparable post-mortem performance between methods and matrices. Whole blood BHB showed the best performance for predicting all-cause ketoacidosis on the meter, despite exhibiting a higher device error messages than vitreous humor. Glucose in vitreous humor exhibited the most optimal performance (100 % sensitivity and specificity) but showed the highest rate of error messages (64 %). Thus, whole blood glucose (80 % sensitivity, 98 % specificity) would be the preferred matrix to identify potential DKA-related deaths. Agreement between meter and laboratory methods was excellent despite differing thresholds (96-100 %).
    CONCLUSIONS: This study suggests that post-mortem BHB levels in whole blood and vitreous humor can be conveniently obtained using the StatStrip meter and have comparable performance to current standards, making it suitable as a screening tool for ketoacidosis-related death. Screening thresholds recommended are vitreous humor (≥ 0.9 mmol/L) or whole blood (≥ 1.6 mmol/L) BHB for ketoacidosis-related death, followed by whole blood glucose (≥ 27.3 mmol/L) for DKA-related death.
    Keywords:  Autopsy; Beta-hydroxybutyrate (BHB); Glucose; Ketoacidosis; Point-of-care; post-mortem
    DOI:  https://doi.org/10.1016/j.forsciint.2024.112358
  10. Front Immunol. 2025 ;16 1550226
      Cardiovascular disease (CVD) continues to be the leading cause of mortality worldwide. The nucleotide oligomerization domain-, leucine-rich repeat-, and pyrin domain-containing protein 3 (NLRP3) inflammasome is involved in numerous types of CVD. As part of innate immunity, the NLRP3 inflammasome plays a vital role, requiring priming and activation signals to trigger inflammation. The NLRP3 inflammasome leads both to the release of IL-1 family cytokines and to a distinct form of programmed cell death called pyroptosis. Inflammation related to CVD has been extensively investigated in relation to the NLRP3 inflammasome. In this review, we describe the pathways triggering NLRP3 priming and activation and discuss its pathogenic effects on CVD. This study also provides an overview of potential therapeutic approaches targeting the NLRP3 inflammasome.
    Keywords:  NLRP3; cardiovacsular diseases; inflammasome; inflammation; pyroptosis
    DOI:  https://doi.org/10.3389/fimmu.2025.1550226
  11. Sci Rep. 2025 Mar 11. 15(1): 8419
      Low-carbohydrate, high-fat diets enhance lipid metabolism and decrease reliance on glucose oxidation in athletes, but the associated gene expression patterns remain unclear. The purpose of this study was to determine whether coordinated molecular pathways in skeletal muscle may be revealed by differential expression of genes driven by dietary profile, exercise, and/or their interaction. We investigated the skeletal muscle transcriptome in elite ultra-endurance athletes habitually (~ 20 months) consuming a high-carbohydrate, low-fat (HC, n = 10, 33 ± 6y, VO2max = 63.4 ± 6.2 mL O2•kg-1•min-1) or low-carbohydrate, high-fat (LC, n = 10, 34 ± 7y, VO2max = 64.7 ± 3.7 mL O2•kg-1•min-1) diet. Skeletal muscle gene expression was measured at baseline (BL), immediately-post (H0), and 2 h (H2) after 3 h submaximal treadmill running. Diet induced a coordinated but divergent expression pattern at BL where LC had higher expression of genes associated with lipid metabolism. Exercise resulted in a dynamic but uniform gene response, with no major differences between groups (H0). At H2, gene expression patterns were associated with differential pathway activity, including inflammation/immunity, suggesting a diet-specific influence on early muscle recovery. These results indicate that low-carbohydrate, high-fat diets lead to differences in resting and exercise-induced skeletal muscle gene expression patterns, underlying our previous findings of differential fuel utilization in elite ultra-endurance athletes.
    DOI:  https://doi.org/10.1038/s41598-025-88963-9
  12. Sci Rep. 2025 Mar 08. 15(1): 8101
      Growth differentiation factor-15 (GDF15) is a biomarker of multiple disease states and circulating GDF15 levels are increased during aging in both pre-clinical animal models and human studies. Accordingly, multiple stressors have been identified, including mitochondrial dysfunction, that lead to induction of Gdf15 expression downstream of the integrated stress response (ISR). For some disease states, the source of increased circulating GDF15 is evident based on the specific pathology. Aging, however, presents a less tractable system for understanding the source of increased plasma GDF15 levels in that cellular dysfunction with aging can be pleiotropic and heterogeneous. To better understand which organ or organs contribute to increased circulating GDF15 levels with age, and whether changes in metabolic and mitochondrial dysfunction were associated with these potential changes, we compared young 12-week-old and middle-aged 52-week-old C57BL/6 J mice using a series of metabolic phenotyping studies and by comparing circulating levels of GDF15 and tissue-specific patterns of Gdf15 expression. Overall, we found that Gdf15 expression was increased in skeletal muscle but not liver, white or brown adipose tissue, kidney or heart of middle-aged mice, and that insulin sensitivity and mitochondrial respiratory capacity were impaired in middle-aged mice. These data suggest that early changes in skeletal muscle mitochondrial function and metabolism contribute to increased circulating GDF15 levels observed during aging.
    Keywords:  Aging; Energy expenditure; Insulin resistance; Integrated stress response; Respirometry
    DOI:  https://doi.org/10.1038/s41598-025-92572-x
  13. Kidney360. 2025 Mar 11.
       BACKGROUND: Several studies suggest that dietary beta hydroxybutyrate supplementation delays the progression of chronic kidney disease (CKD) by suppressing inflammation and fibrosis. We hypothesized that the oral supplementation with the beta-hydroxybutyrate (BHB) precursor 1,3-butanediol in addition to inhibitors of the renin-angiotensin system (RAS) and sodium-glucose transporter (SGLT)2 would be superior to dual RAS/SGLT2 blockade alone in attenuating the loss of glomerular filtration rate in Col4a3-deficient mice with Alport nephropathy, a spontaneous model of progressive CKD.
    METHODS: We performed a placebo-controlled study in Col4a3-deficient mice with Alport nephropathy. Treatment was initiated at a late stage of the disease at the age of six weeks. Mice were fed food admixes of 10 μg/g ramipril plus 30 μg/g empagliflozin with or without addition of 0,04g/g 1,3-butanediol (concentration per gram of bodyweight). The mice were monitored daily and sacrificed upon reaching renal failure. The glomerular filtration rate (GFR) was measured at the start of the treatment and after one and four weeks.
    RESULTS: The addition of beta hydroxybutyrate significantly attenuated the loss of glomerular filtration rate beyond the effect of dual RAS/SGLT2 blockade. The mean glomerular filtration rate after four weeks of treatment was 1.4±5.0 μl/min (vehicle), 61.3±51.1 μl/min (RASi + SGLT2i), and 138.9±68.5 μl/min (RASi + SGLT2i + 1,3-butanediol). No additional effects on lifespan could be observed. Kidney RNA sequencing revealed significant protective effects on inflammation when adding the beta hydroxybutyrate precursor 1,3-butanediol to RAS/SGLT2 inhibition. In histopathology, antifibrotic effects were seen upon beta hydroxybutyrate addition.
    CONCLUSIONS: The results in mice suggest that beta hydroxybutyrate supplementation improves the GFR in Alport syndrome by suppressing inflammation and fibrosis. However, the effects did not lead to a significant increase in lifespan. Furthermore, the observed effects stay behind the effects of finerenone as a combination partner, which was tested earlier in the same mouse model.
    DOI:  https://doi.org/10.34067/KID.0000000747
  14. Diabetes Res Clin Pract. 2025 Mar 08. pii: S0168-8227(25)00095-6. [Epub ahead of print]222 112081
       AIMS: Time-restricted eating (TRE) is a chrono-nutrition strategy where the daily 'eating window' is reduced to 8-10 h. We investigated the acute (14-h) effects of TRE, with and without post-meal exercise, on blood glucose and insulin concentrations in people with type 2 diabetes mellitus.
    METHODS: Fourteen participants (5 F, 9 M; HbA1c: 7.6 ± 1.0%) completed four conditions in this randomised crossover study: CON (eating window, 0800-2000 h), CON with exercise (CON + Ex; 0800-2000 h + 15 min walking at 60% VO2peak, 45 min post-meal), TRE (eating window 1000-1800 h), and TRE with exercise (TRE + Ex, 1000-1800 h + 15 min walking as per CON + Ex), with standardised meals. Venous blood samples were collected at 26-timepoints and analysed for glucose and insulin concentrations. Statistical analysis used linear mixed-effects models with P < 0.05.
    RESULTS: Reducing the eating window had little effect on plasma glucose 14-h area under the curve (AUC). Exercise reduced insulin 14-h AUC (P=0.01) with no additive effect of TRE.
    CONCLUSION: Post-meal exercise lowered 14-h insulin AUC, neither 8-h TRE nor post-meal exercise altered 14-h blood glucose compared with 12-h eating window. Future work should focus on long-term effects of TRE combined with exercise for enhancing blood glucose in people with type 2 diabetes mellitus.
    Keywords:  Exercise timing; Glucose; Insulin; Meal timing; Time-restricted eating; Type 2 diabetes mellitus
    DOI:  https://doi.org/10.1016/j.diabres.2025.112081
  15. Peptides. 2025 Mar 08. pii: S0196-9781(25)00042-7. [Epub ahead of print]187 171381
      The NLRP3 inflammasome plays a crucial role as a critical regulator of the immune response and has been implicated in the pathogenesis of numerous diseases. Peptides, known for their remarkable potency, selectivity, and low toxicity, have been extensively employed in disease treatment. Recent research has unveiled the potential of peptides in modulating the activity of the NLRP3 inflammasome. This review begins by examining the structure of the NLRP3 inflammasome, encompassing NLRP3, ASC, and Caspase-1, along with the three activation pathways: canonical, non-canonical, and alternative. Subsequently, we provide a comprehensive summary of peptide modulators targeting the NLRP3 inflammasome and elucidate their underlying mechanisms. The efficacy of these modulators has been validated through in vitro and in vivo experiments on NLRP3 inflammasome regulation. Furthermore, we conduct sequence alignment of the identified peptides and investigate their binding sites on the NLRP3 protein. This work is a foundational exploration for advancing peptides as potential therapeutic agents for NLRP3-related diseases.
    Keywords:  NLRP3 inflammasome; Peptides
    DOI:  https://doi.org/10.1016/j.peptides.2025.171381
  16. Physiol Genomics. 2025 Mar 10.
      Aging is the primary risk factor for the development of many chronic diseases, including dementia, cardiovascular disease, and diabetes. There is significant interest in identifying novel "geroprotective" agents, including by repurposing existing drugs, but such treatments may affect organ systems differently. One current example is the nucleoside reverse transcriptase inhibitor 3TC, which has been increasingly studied as a potential gerotherapeutic. Recent data suggest 3TC may reduce inflammation and improve cognitive function in older mice; however, the effects of 3TC on other tissues in aged animals are less well characterized. Here, we use transcriptomics (RNA-seq) and targeted metabolomics to investigate the influence of 3TC supplementation on skeletal muscle in older mice. We show that 3TC: (a) does not overtly affect muscle mass or functional/health markers; (b) largely reverses age-related changes in gene expression and metabolite signatures; and (c) is potentially beneficial for mitochondrial function in old animals via increases in antioxidant enzymes and decreases in mitochondrial reactive oxygen species. Collectively, our results suggest that, in addition to its protective effects in other tissues, 3TC supplementation does not have adverse effects in aged muscle, and may even protect muscle/mitochondrial health in this context.
    Keywords:  aging; metabolomics; mitochondria; skeletal muscle; transcriptomics
    DOI:  https://doi.org/10.1152/physiolgenomics.00115.2024
  17. Liver Int. 2025 Apr;45(4): e70068
       BACKGROUND AND AIMS: Notch1 protein plays a significant role in hepatic metabolism, as evidenced by its correlation with insulin resistance in the livers of obese individuals, making it an intriguing research target. Therefore, this study aims to investigate the impact of aerobic exercise on Notch1 pathways in the hepatic tissue of obese mice and its role in controlling hepatic metabolism.
    METHODS: Therefore, we conducted a cross-sectional study utilising liver biopsies from lean and obese humans, as well as an intervention study involving mice subjected to a high-fat diet. The obese-trained mice group underwent a treadmill-running protocol for 4 weeks.
    RESULTS: Our findings revealed that obese individuals exhibited increased NOTCH1 mRNA levels compared to lean subjects. The detrimental effects of Notch1 signalling were confirmed by Notch1-overexpressed HepG2 cell lines. Obese mice with higher hepatic Notch1 signalling demonstrated a reduction in this pathway when subjected to a 4-week treadmill running. Another benefit noticed in this trained group was the amelioration of insulin resistance, as well as a reduction in pyruvate intolerance and gluconeogenic enzymes. Additionally, we observed that these protective findings were accompanied by a decrease in mTORC1 pathway activity and lipid accumulation in the liver. Pharmacological inhibition of Notch1 in obese mice led to an increase in mitochondrial respiration in the liver.
    CONCLUSIONS: We conclude that Notch1 signalling may be a potentially useful therapeutic target in obesity, while aerobic exercise training suppresses the Notch1 pathway in the liver, contributing to the regulation of hepatic glucose and lipid metabolism in obese mice.
    Keywords:  MAFLD; gluconeogenesis; lipogenesis; physical exercise
    DOI:  https://doi.org/10.1111/liv.70068
  18. Nature. 2025 Mar 12.
      
    Keywords:  Ageing; Brain; Genetics
    DOI:  https://doi.org/10.1038/d41586-025-00766-0
  19. EMBO J. 2025 Mar 10.
      During homeostasis and regeneration, satellite cells, the resident stem cells of skeletal muscle, have distinct metabolic requirements for fate transitions between quiescence, proliferation and differentiation. However, the contribution of distinct energy sources to satellite cell metabolism and function remains largely unexplored. Here, we uncover a role of mitochondrial fatty acid oxidation (FAO) in satellite cell integrity and function. Single-cell RNA sequencing revealed progressive enrichment of mitochondrial FAO and downstream pathways during activation, proliferation and myogenic commitment of satellite cells. Deletion of Carnitine palmitoyltransferase 2 (Cpt2), the rate-limiting enzyme in FAO, hampered muscle stem cell expansion and differentiation upon acute muscle injury, markedly delaying regeneration. Cpt2 deficiency reduces acetyl-CoA levels in satellite cells, impeding the metabolic flux and acetylation of selective proteins including Pax7, the central transcriptional regulator of satellite cells. Notably, acetate supplementation restored cellular metabolic flux and partially rescued the regenerative defects of Cpt2-null satellite cells. These findings highlight an essential role of fatty acid oxidation in controlling satellite cell function and suggest an integration of lipid metabolism and protein acetylation in adult stem cells.
    Keywords:  CPT2; Fatty Acid Oxidation; Muscle Regeneration; Muscle Satellite Cell; Protein Acetylation
    DOI:  https://doi.org/10.1038/s44318-025-00397-1
  20. Int J Mol Sci. 2025 Feb 27. pii: 2136. [Epub ahead of print]26(5):
      To explore the molecular mechanism of aerobic exercise to improve heart failure and to provide a theoretical basis and experimental reference for the treatment of heart failure. Nine-week-old male mice were used to establish a left ventricular pressure overload-induced heart failure model by transverse aortic constriction (TAC). The mice were randomly divided into four groups: a sham group (SHAM), heart failure group (HF), heart failure + SKQ1 group (HS) and heart failure + aerobic exercise group (HE). The mice in the HE group were subjected to moderate-intensity aerobic exercise interventions. The mitochondrion-targeting antioxidant (SKQ1) contains the lipophilic cation TPP, which targets scavenging mitochondrial ROS. The HS group was subjected to SKQ1 (100 nmol/kg/d) interventions, which were initiated 1 week after the surgery, and the interventions lasted 8 weeks. Cardiac function was assessed by ultrasound, cardiomyocyte size by H&E and WGA staining, myocardial fibrosis by Masson's staining, and myocardial tissue oxidative stress and apoptosis by DHE and TUNEL fluorescence staining, respectively. Western blotting was used to detect the expression of mitochondrial quality control, inflammation, and apoptosis-related proteins. In the cellular level, an in vitro cellular model was established by isolating primary cardiomyocytes from neonatal mice (2-3 days) and intervening with Ang II (1 μM) to mimic heart failure. Oxidative stress and mitochondrial membrane potential were determined in the cardiomyocytes of each group by DHE and JC-1 staining, respectively. Myocardial fibrosis was increased significantly and cardiac function was reduced significantly in the heart failure mice. Aerobic exercise and SKQ1 intervention improved cardiac function and reduced myocardial hypertrophy and myocardial fibrosis in the heart failure mice significantly. Meanwhile, aerobic exercise and SKQ1 intervention reduced the number of DHE-positive particles (p < 0.01) and inhibited myocardial oxidative stress in the heart failure mice significantly. Aerobic exercise also reduced DRP1, Parkin, and BNIP3 protein expression (p < 0.05, p < 0.01), and increased OPA1 and PINK1 protein expression (p < 0.05, p < 0.01) significantly. Moreover, aerobic exercise and SKQ1 intervention decreased the number of TUNEL-positive particles and the expression of inflammation- and apoptosis-related proteins NLRP3, TXNIP, Caspase-1, IL-1β, BAX, BAK, and p53 significantly (p < 0.05, p < 0.01). In addition, the AMPK agonist AICAR and the mitochondria-targeted ROS scavenger (SKQ1) ameliorated AngII-induced mitochondrial fragmentation and decreased mitochondrial membrane potential in cardiomyocytes significantly. It was shown that inhibition of mitochondrial ROS by aerobic exercise, which in turn inhibits mitochondrial damage, improves mitochondrial quality control, and reduces myocardial inflammatory and apoptosis, may be an important molecular mechanism by which aerobic exercise exerts endogenous antioxidant protective effects to improve cardiac function.
    Keywords:  aerobic exercise; apoptosis; heart failure; inflammation; mitochondrial quality control; oxidative stress
    DOI:  https://doi.org/10.3390/ijms26052136
  21. Nutrients. 2025 Feb 20. pii: 750. [Epub ahead of print]17(5):
       BACKGROUND: Skeletal muscle, as the largest organ in the body and the main protein pool, is crucial for various physiological processes, but atrophy of skeletal muscle can result from glucocorticoids, including dexamethasone, or from aging. Astaxanthin (AST) is a ketocarotenoid with a variety of physiological activities. However, the clinical application of AST is hampered by its strong hydrophobicity, intense off-flavors, and susceptibility to oxidation.
    METHODS: In this study, we prepared whey protein isolate (WPI)-encapsulated AST nanoemulsion (WPI-AST, W-A) and investigated its alleviating effects on dexamethasone-induced skeletal muscle atrophy.
    RESULTS: The optimal concentration of astaxanthin was determined to be 30 mg/mL with an oil/water ratio of 1:5. The W-A was a typical oil-in-water (O/W) emulsion with a particle size of about 110 nm. The bioaccessibility of astaxanthin was significantly improved, with the off-flavors of astaxanthin effectively masked. After oral administration, the W-A further ameliorated skeletal muscle atrophy by inhibiting skeletal muscle catabolism, promoting skeletal muscle production, and inhibiting mitochondrial autophagy compared with the same dose of WPI and AST. In addition to this, the W-A further improved the glycometabolism of skeletal muscle by reducing the expression of Foxo3 and increasing the expression of PGC-1α.
    CONCLUSIONS: In conclusion, the W-A nanoemulsion demonstrated good therapeutic value in alleviating skeletal muscle atrophy.
    Keywords:  astaxanthin; dexamethasone; nanoemulsion; skeletal muscle atrophy; whey protein isolate
    DOI:  https://doi.org/10.3390/nu17050750
  22. Eur J Med Chem. 2025 Mar 04. pii: S0223-5234(25)00231-4. [Epub ahead of print]289 117466
      Targeting NLRP3 is a highly promising strategy for treating uncontrolled inflammation, which can cause a wide range of diseases or promote disease progression. More NLRP3-targeting inhibitors with different scaffolds are needed to increase the chances of developing safe and effective NLRP3 inhibitors and treating inflammation in different tissues. Here, we discovered the novel quinoline analogues that exhibit potent inhibitory activity against the NLRP3/IL-1β pathway in J774A.1, BMDMs, and human peripheral blood cells. Mechanistic studies confirmed W16 may directly target NLRP3 and block the NLRP3 inflammasome assembly and activation. In vitro studies demonstrated that W16 has potent anti-inflammatory effects on DSS-induced ulcerative colitis model. Our findings demonstrated that W16 is a potential lead compound targeting NLRP3 and deserves further investigation for the treatment of NLRP3-related inflammatory diseases.
    Keywords:  Colitis; Inhibitor; NLRP3; Quinoline
    DOI:  https://doi.org/10.1016/j.ejmech.2025.117466
  23. Eur J Pharmacol. 2025 Mar 06. pii: S0014-2999(25)00209-2. [Epub ahead of print] 177455
      Diabetic stroke-associated acute intestinal injury is characterized by high mortality, disability, and poor prognosis due to the lack of effective therapies. Our prior research demonstrated that administration of 300 mg/kg sodium butyrate (NaB) can improve neurological outcomes post-diabetic stroke. Nonetheless, whether the effect of NaB is related to intestinal regulation, along with its underlying mechanisms, remains uncertain. This study aims to investigate the effects and mechanistic pathways of NaB on diabetic stroke-associated acute intestinal injury. A middle cerebral artery occlusion/reperfusion model was established in mice with streptozotocin-induced diabetes. The results demonstrated that NaB alleviated colonic injury 24 hours after reperfusion in diabetic stroke. Pyroptosis-related protein levels in colonic tissues were significantly elevated following diabetic stroke but were markedly reduced with NaB treatment. NaB also improved gut barrier integrity and reduced inflammation, promoting epithelial barrier self-repair. In the NaB combined with lipopolysaccharide group, lipopolysaccharide administration induced a significant inflammatory response in the colonic tissue. Conversely, treatment with NaB and VX-765 (an inhibitor for Caspase-1) led to a notable alleviation in intestinal inflammation. These findings suggest that NaB mitigates colonic injury and enhances barrier function following diabetic stroke, potentially through the Caspase-1/Gasdermin D pyroptosis pathway. This study may provide a novel strategy and direction for intestinal rehabilitation in diabetic stroke patients.
    Keywords:  Colon; Diabetic stroke; Intestinal barrier; Neurological intensive care; Pyroptosis
    DOI:  https://doi.org/10.1016/j.ejphar.2025.177455
  24. J Physiol. 2025 Mar 09.
      Obesity is associated with insulin resistance (IR) development, a risk factor for type 2 diabetes (T2D). How mitochondrial bioenergetics, in adipose tissue (AT), differs according to distinct metabolic profiles (i.e. insulin sensitive (IS), IR normoglycaemic (IR-NG), pre-diabetes (PD) and T2D) is still poorly understood. The purpose of this study was to evaluate and compare bioenergetics and energy substrate preference by omental AT (OAT) and subcutaneous AT (SAT) from subjects with obesity (OB, n = 40) at distinct metabolic stages. Furthermore, AT bioenergetics was also evaluated pre- and post-bariatric/metabolic surgery (BMS). High-resolution respirometry (HRR) was used to measure the real-time oxidative phosphorylation (OXPHOS) capacity and mitochondrial substrate preferences in both tissues. Substrate-uncoupler-inhibitor titration protocols were used: SUIT-P1 (complex I and II-linked mitochondrial respiration) and SUIT-P2 (fatty acid oxidation (FAO)-linked mitochondrial respiration). Flux control ratios (FCRs) were calculated. In SUIT-P1, lower OXPHOS capacity was observed in AT, particularly in SAT, during the establishment of IR (OB-IR-NG) and in the T2D group, due to alterations of mitochondrial coupling, evaluated by FCRs. In SUIT-P2, the OXPHOS coupling efficiency was highest in the OB-IR-NG group. AT from OB-IS, OB-IR-NG and OB-IR-PD preferred pyruvate, malate and glutamate oxidation and/or FAO during OXPHOS, whereas AT from T2D preferred succinate oxidation. BMS enhanced mitochondrial respiration in OAT, even under poor OXPHOS coupling efficiency. In conclusion, real-time OXPHOS analysis by HRR may be a sensitive biomarker of mitochondrial fitness, particularly in AT. Interventions based on modulating energetic substrate availability may become a good tool for obesity treatment stratification. KEY POINTS: Omental adipose tissue shows higher oxidative phosphorylation (OXPHOS) capacity compared to subcutaneous adipose tissue in paired explants from subjects with obesity. The OXPHOS capacity of adipose tissue differs through the progression of metabolic disease. Subjects with obesity and diabetes have the lowest OXPHOS capacity in paired explants of subcutaneous and omental adipose tissues. Bariatric surgery enhanced the OXPHOS capacity in omental adipose tissue, even under poor OXPHOS coupling efficiency. Assessment of the oxidative capacity in fresh adipose tissue explants could be a sensitive tool for early diagnosis of metabolic disease.
    Keywords:  OXPHOS capacity; adipose tissue; bariatric surgery; insulin resistance; mitochondria; obesity; type 2 diabetes
    DOI:  https://doi.org/10.1113/JP286103
  25. Mol Med Rep. 2025 May;pii: 127. [Epub ahead of print]31(5):
      Mitochondria‑derived peptides (MDPs) are a unique class of peptides encoded by short open reading frames in mitochondrial DNA, including the mitochondrial open reading frame of the 12S ribosomal RNA type‑c (MOTS‑c). Recent studies suggest that MDPs offer therapeutic benefits in various diseases, including neurodegenerative disorders and types of cancer, due to their ability to increase cellular resilience. Mitochondrial dysfunction is a key factor in the onset and progression of cardiovascular diseases (CVDs), such as atherosclerosis and heart failure, as it disrupts energy metabolism, increases oxidative stress and promotes inflammation. MDPs such as humanin and MOTS‑c have emerged as important regulators of mitochondrial health, as they show protective effects against these processes. Recent studies have shown that MDPs can restore mitochondrial function, reduce oxidative damage and alleviate inflammation, thus counteracting the pathological mechanisms that drive CVDs. Therefore, MDPs hold promise as therapeutic agents that are capable of slowing, stopping, or even reversing CVD progression and their use presents a promising strategy for future treatments. However, the clinical application of MDPs remains challenging due to their low bioavailability, poor stability and high synthesis costs. Thus, it is necessary to improve drug delivery systems to enhance the bioavailability of MDPs. Moreover, integrating basic research with clinical trials is essential to bridge the gap between experimental findings and clinical applications.
    Keywords:  cardiovascular diseases; inflammation; mechanism; mitochondria; mitochondria‑derived peptides
    DOI:  https://doi.org/10.3892/mmr.2025.13492